Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 612.82M +126.0% |
| Revenue (ttm) | n/a |
| Net Income | -147.50M |
| EPS | -2.65 |
| Shares Out | 58.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,003,413 |
| Open | 9.65 |
| Previous Close | 8.87 |
| Day's Range | 8.98 - 10.75 |
| 52-Week Range | 2.96 - 40.37 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 27.00 (+156.17%) |
| Earnings Date | Nov 10, 2026 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price target is $27.0, which is an increase of 156.17% from the latest price.
News
Opco sees Capricor shares moving to $50 on FDA approval
Oppenheimer says Capricor Therapeutics (CAPR)’ Q3 update reiterated the “abundance of support” for deramiocel to slow skeletal muscle function decline and cardiomyopathy progression in Duchenne. The f...
Capricor Therapeutics upgraded to Buy from Hold at Jones
Jones upgraded Capricor Therapeutics (CAPR) to Buy from Hold with a $25 price target ahead of the November 22 PDUFA deadline for deramiocel. The firm’s new price target is based…
Capricor Therapeutics reports Q3 EPS (73c), consensus (41c)
“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing…
Capricor Therapeutics Earnings Call Transcript: Q3 2026
HOPE-3 and integrated data supported Deramiocel as the FDA review neared its November 22 target date. Quarter-end cash and marketable securities were $198.5M, while launch readiness advanced.
Capricor Therapeutics Earnings release: Q3 2026
Capricor Therapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Capricor Therapeutics Quarterly report: Q3 2026
Capricor Therapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor Therapeutics Transcript: Study result
HOPE-3 and pooled HOPE-2/HOPE-3 analyses showed preservation of upper-limb function, with OLE data supporting sustained effects. Cardiac findings and safety follow-up were also presented ahead of the Nov. 22 PDUFA date.
Capricor Therapeutics Press release: Study result
Capricor Therapeutics issued a press release on October 7, 2026, disclosing material business information to investors.
Capricor Therapeutics Slides: Study result
Capricor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
Capricor Therapeutics call buyer realizes 94% same-day gains
Notable profits for the buyer who lifted the $0.56 offer for 2,768 Capricor Therapeutics (CAPR) 11/13 weekly 10 calls yesterday at 15:28ET when underlying shares were trading at $7.72. Shares…
Roth sees second FDA panel as possibility for Capricor
Roth Capital believes Capricor Therapeutics (CAPR)’ open label extension data this morning strengthens deramiocel’s upper-limb efficacy. However, early-start separation was modest, safety disclosure w...
H.C. Wainwright sees complete response letter as most likely for Capricor
H.C. Wainwright views Capricor Therapeutics (CAPR)’ 24-month open-label extension data as “encouraging,” with slower modeled PUL 2.0 decline after placebo patients crossed over to deramiocel. The data...
Capricor announces open-label extension data for Deramiocel
Capricor Therapeutics (CAPR) this morning announced new data from its ongoing HOPE-3 open-label extension study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne m...
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline...
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to Their Right to Seek Lead Plaintiff Status Before September 29, 2026
New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Seek a Leadership Role Before September 28, 2026
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
Kaplan Fox & Kilsheimer LLP Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Ahead of the Lead Plaintiff Deadline on September 29, 2026
New York, New York--(Newsfile Corp. - September 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
$CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
Philadelphia, Pennsylvania--(Newsfile Corp. - September 22, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR)...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Caprico...